Rigel, of South San Francisco, California, is positioning R788 (tamatinib fodium), an inhibitor of Syk kinase, as a direct challenger to the tumor necrosis factor-alpha (TNF-α) inhibitor biologics.

Of the kinase inhibitors in the drug development pipeline, the upstream Janus kinase (JAK) and spleen tyrosine kinase (Syk) targets are closer to the cell surface, and seem more promising targets ...

Fostamatinib is a Syk inhibitor that has been demonstrated to be effective in improving signs and symptoms of disease and improving health-related quality of life and physical function in dose ...

Building on the success of targeting protein tyrosine kinases in oncology, RCTs of inhibitors to the tyrosine kinases, Jak and Syk, have been ongoing (Table 1). Results have been either presented ...

SYK inhibitor Tavlesse was approved in the US last year for ITP, an acquired immune-mediated disorder characterised by destruction of platelets and impaired platelet production, under the ...

Dropping istisociclib caps off a tough 12 months for Kronos that saw two rounds of layoffs and work halted on the SYK inhibitor lanraplenib. While it didn’t warrant a mention in yesterday’s ...

Grifols – a Barcelona-based specialist in plasma-based therapies – said today that Tavlesse is the first and only SYK inhibitor for patients with ITP, an autoimmune clotting disorder that ...

NCI will include the multi-kinase inhibitor in the umbrella trial evaluating targeted therapy combinations in AML and MDS patients.